Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT03275103
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This is a study where doctors test a new medicine called cevostamab on people who have multiple myeloma and it has come back or has not gone away. The medicine will be given through a vein and they will start with a low dose and increase it slowly to see if it is safe and if it works.
This is a study where doctors test a new medicine called cevostamab on people who have multiple myeloma and it has come back or has not gone away. The medicine will be given through a vein and they will start with a low dose and increase it slowly to see if it is safe and if it works.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
